{"id":"aju-s56-5","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1916982","moleculeType":"Small molecule","molecularWeight":"341.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AJU-S56 5% reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"AJU-S56 5% is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:17.604Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06337981","phase":"PHASE2","title":"Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients","status":"COMPLETED","sponsor":"AJU Pharm Co., Ltd.","startDate":"2021-11-22","conditions":"Dry Eye Syndromes","enrollment":99},{"nctId":"NCT06291194","phase":"PHASE3","title":"Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients","status":"RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2023-11-10","conditions":"Dry Eye Syndromes","enrollment":396}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6778553,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Test Group","Test 2 group(AJU-S56 5%, 1 drop/1time, 6times in a day)"],"phase":"phase_3","status":"active","brandName":"AJU-S56 5%","genericName":"AJU-S56 5%","companyName":"AJU Pharm Co., Ltd.","companyId":"aju-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AJU-S56 5% is a small molecule being studied for its efficacy and safety in treating Dry Eye Syndromes. The clinical trial, NCT06291194, is evaluating the effectiveness of AJU-S56 5% compared to a placebo after 24 weeks of administration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}